National Multiple Sclerosis Society. Disease-modifying therapies for MS 2022. https://www.nationalmssociety.org/managingms/treating-ms/disease-modifying-therapies. Accessed 9 Dec 2022

Burtchell J, Clemmons D, Clemmons J, et al. A targeted literature search and phenomenological review of perspectives of people with multiple sclerosis and healthcare professionals of the immunology of disease-modifying therapies. Neurol Ther. 2022;11(3):955–79.

Article  PubMed  PubMed Central  Google Scholar 

Cohan SL, Moses H, Calkwood J, et al. Clinical outcomes in patients with relapsing-remitting multiple sclerosis who switch from natalizumab to delayed-release dimethyl fumarate: a multicenter retrospective observational study (STRATEGY). Mult Scler Relat Disord. 2018;22:27–34.

Article  PubMed  Google Scholar 

Kresa-Reahl K, Repovic P, Robertson D, Okwuokenye M, Meltzer L, Mendoza JP. Effectiveness of delayed-release dimethyl fumarate on clinical and patient-reported outcomes in patients with relapsing multiple sclerosis switching from glatiramer acetate: RESPOND, a prospective observational study. Clin Ther. 2018;40(12):2077–87.

Article  CAS  PubMed  Google Scholar 

Rae-Grant A, Day GS, Marrie RA, et al. Practice guideline recommendations summary: disease-modifying therapies for adults with multiple sclerosis: report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. Neurology. 2018;90(17):777–88.

Article  PubMed  Google Scholar 

Sellebjerg F, Blinkenberg M, Sorensen PS. Anti-CD20 monoclonal antibodies for relapsing and progressive multiple sclerosis. CNS Drugs. 2020;34(3):269–80.

Article  CAS  PubMed  Google Scholar 

Fernández-Velasco JI, Kuhle J, Monreal E, et al. Effect of ocrelizumab in blood leukocytes of patients with primary progressive MS. Neurol Neuroimmunol Neuroinflamm. 2021;8(2):e940.

Article  PubMed  PubMed Central  Google Scholar 

Nicholas JA, Gudesblatt M, Garabedian M, et al. Dimethyl fumarate is associated with lower rates of infection and lower infection-related healthcare costs when compared with ocrelizumab. Mult Scler Relat Disord. 2022;63: 103921.

Article  CAS  PubMed  Google Scholar 

Luna G, Alping P, Burman J, et al. Infection risks among patients with multiple sclerosis treated with fingolimod, natalizumab, rituximab, and injectable therapies. JAMA Neurol. 2020;77(2):184–91.

Article  PubMed  Google Scholar 

Peters J, Longbrake EE. Infection risk in a real-world cohort of patients treated with long-term B-cell depletion for autoimmune neurologic disease. Mult Scler Relat Disord. 2022;68:104400.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bar-Or A, Calkwood JC, Chognot C, et al. Effect of ocrelizumab on vaccine responses in patients with multiple sclerosis: the VELOCE study. Neurology. 2020;95(14):e1999–2008.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Achiron A, Mandel M, Dreyer-Alster S, et al. Humoral immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapies. Ther Adv Neurol Disord. 2021;14:17562864211012836.

CAS  PubMed  PubMed Central  Google Scholar 

Tortorella C, Aiello A, Gasperini C, et al. Humoral- and T-cell-specific immune responses to SARS-CoV-2 mRNA vaccination in patients with MS using different disease-modifying therapies. Neurology. 2022;98(5):e541–54.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Rodríguez de Antonio LA, García Castañón I, Aguilar-Amat Prior MJ, Puertas I, González Suárez I, Oreja Guevara C. Non-inflammatory causes of emergency consultation in patients with multiple sclerosis. Neurologia (Engl Ed). 2021;36(6):403–11.

Article  PubMed  Google Scholar 

Mills EA, Mirza A, Mao-Draayer Y. Emerging approaches for validating and managing multiple sclerosis relapse. Front Neurol. 2017;8:116.

Article  PubMed  PubMed Central  Google Scholar 

Conway SE, Healy BC, Zurawski J, et al. COVID-19 severity is associated with worsened neurological outcomes in multiple sclerosis and related disorders. Mult Scler Relat Disord. 2022;63: 103946.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Buljevac D, Flach HZ, Hop WC, et al. Prospective study on the relationship between infections and multiple sclerosis exacerbations. Brain. 2002;125(Pt 5):952–60.

Article  CAS  PubMed  Google Scholar 

Satyanarayan S, Safi N, Sorets T, et al. Differential antibody response to COVID-19 vaccines across immunomodulatory therapies for multiple sclerosis. Mult Scler Relat Disord. 2022;62: 103737.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Jakubecz C, Zhang XS, Woodson S, Serra A, Abboud H. The humoral response to SARS-COV-2 vaccines in MS patients: a case series exploring the impact of DMT, lymphocyte count, immunoglobulins, and vaccine type. Mult Scler Relat Disord. 2022;61:103785.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Corboy JR, Fox RJ, Kister I, et al. Risk of new disease activity in patients with multiple sclerosis who continue or discontinue disease-modifying therapies (DISCOMS): a multicentre, randomised, single-blind, phase 4, non-inferiority trial. Lancet Neurol. 2023;22(7):568–77.

Article  PubMed  Google Scholar 

Biogen. Vumerity [Summary of Product Characteristics]. Netherlands2023. p. 2–3.

Biogen. Vumerity [Prescribing Information]. Cambridge, MA2023.

Biogen. Data on file.

Wray S, Then Bergh F, Wundes A, et al. Efficacy and safety outcomes with diroximel fumarate after switching from prior therapies or continuing on DRF: results from the phase 3 EVOLVE-MS-1 study. Adv Ther. 2022;39(4):1810–31.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sormani MP, De Rossi N, Schiavetti I, et al. Disease-modifying therapies and coronavirus disease 2019 severity in multiple sclerosis. Ann Neurol. 2021;89(4):780–9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Simpson-Yap S, De Brouwer E, Kalincik T, et al. Associations of disease-modifying therapies with COVID-19 severity in multiple sclerosis. Neurology. 2021;97(19):e1870–85.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Polman CH, Reingold SC, Banwell B, et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol. 2011;69(2):292–302.

Article  PubMed  PubMed Central  Google Scholar 

Golan D, Wilken J, Doniger GM, et al. Validity of a multi-domain computerized cognitive assessment battery for patients with multiple sclerosis. Mult Scler Relat Disord. 2019;30:154–62.

Article  PubMed  Google Scholar 

Kappos L, Wolinsky JS, Giovannoni G, et al. Contribution of relapse-independent progression vs relapse-associated worsening to overall confirmed disability accumulation in typical relapsing multiple sclerosis in a pooled analysis of 2 randomized clinical trials. JAMA Neurol. 2020;77(9):1132–40.

Article  PubMed  Google Scholar 

Teter B, Agashivala N, Kavak K, Chouhfeh L, Hashmonay R, Weinstock-Guttman B. Characteristics influencing therapy switch behavior after suboptimal response to first-line treatment in patients with multiple sclerosis. Mult Scler. 2014;20(7):830–6.

Article  PubMed  Google Scholar 

Galetta KM, Calabresi PA, Frohman EM, Balcer LJ. Optical coherence tomography (OCT): imaging the visual pathway as a model for neurodegeneration. Neurotherapeutics. 2011;8(1):117–32.

Article  PubMed  PubMed Central  Google Scholar 

Pearson T, Chen Y, Dhillon B, Chandran S, van Hemert J, MacGillivray T. Multi-modal retinal scanning to measure retinal thickness and peripheral blood vessels in multiple sclerosis. Sci Rep. 2022;12(1):20472.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bsteh G, Hegen H, Teuchner B, et al. Peripapillary retinal nerve fibre layer as measured by optical coherence tomography is a prognostic biomarker not only for physical but also for cognitive disability progression in multiple sclerosis. Mult Scler. 2019;25(2):196–203.